Core Viewpoint - Hyaluronic acid giant, Huaxi Biological Technology Co., Ltd., reported a decrease in total revenue for 2025 while achieving significant profit growth, indicating a focus on cost reduction and structural optimization [1][2]. Group 1: Financial Performance - In 2025, Huaxi Biological achieved total revenue of 4.217 billion yuan, a decrease of 21.49% compared to 5.371 billion yuan in the previous year [1]. - The net profit attributable to the parent company was 291 million yuan, an increase of 67.03% year-on-year [1]. - The net profit attributable to the parent company after deducting non-recurring gains and losses increased by 75.28% to 188 million yuan [1]. Group 2: Cost Management and Structural Optimization - Management expenses decreased by over 10% and sales expenses decreased by over 30% in 2025 [2]. - The company conducted systematic structural optimization around skin science and nutrition science innovation, adjusting its C-end brand system, product structure, and channel models [2]. - The company reduced investments in brands and projects with low return on investment, focusing on core business and major brands [2]. Group 3: Brand Adjustments - In September 2025, the skincare brand "Runxiquan," focused on anti-aging and repair effects, reportedly closed stores [2]. - In November 2025, the online operations of the brand "Dema Run," which emphasizes "customized skin solutions," faced stagnation [2]. - The adjustments of these brands were aimed at optimizing the business structure, despite short-term impacts on revenue [2].

Industry Dynamics - Zhong Shanshan has resigned as the legal representative and financial officer of Yangshengtang (Hangzhou) Health Products E-commerce Co., Ltd., with Chen Kang taking over the role [2] - Seesaw Coffee's associated company, Shanghai Xishe Coffee Co., Ltd., has been listed in the business abnormality directory due to inability to contact the registered address, with total enforcement amounts exceeding 2.99 million [3] - Huaxi Biological's brand DermaRun has closed its online channels, with the company stating this is part of a strategy to focus on core business and improve operational efficiency [3] - LUK Fook Holdings expects a net profit increase of 40% to 50% for the first half of the fiscal year, driven by rising gold prices and increased sales of priced jewelry [4] - Chao Hong Ji is actively expanding its store network and product planning, enhancing its multi-channel business layout [5] - Haolilai has commenced construction of the largest baking R&D and production base in East China, with an investment of 200 million yuan and an expected annual output value of 350 million yuan [6] - Qiaqia Food and Chengdu Zhengchuang Laomofang have established a joint venture, with Qiaqia holding a controlling stake [7] - Mixue Ice City reported sales of over 1.5 billion cups of "Ice Fresh Lemon Water" in the first ten months of the year, with significant improvements in lemon yield from cooperative orchards [8] - Bright Dairy has launched its first pet food brand, "Bright Youyi," offering high-end staple products [9] Financial Performance - Walmart's Q3 net sales in China reached $6.1 billion (approximately 43.4 billion yuan), a year-on-year increase of 21.8%, with comparable sales growing by 13.8% [10] - NetEase reported Q3 revenue of 28.4 billion yuan, a year-on-year increase of 8.4%, with a net profit of 9.5 billion yuan, up 26.67% [21]

Core Viewpoint - Huaxi Biological's Demarun brand has been reported to close its Tmall flagship store and other online channels, which is part of the company's strategy to focus on its core business and major brand layout to enhance overall operational efficiency and resource allocation [1] Group 1 - The adjustment of Demarun's online channels is aimed at improving operational efficiency and resource allocation [1] - Future planning for the Demarun brand will be coordinated based on market and business development conditions [1] - The company emphasizes that all business operations are normal and that brand strategy adjustments are aimed at long-term healthy development [1]